We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Replicel Life Sciences Inc (RP) NPV

Sell:0.01 CAD Buy:0.02 CAD Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.01 CAD
Buy:0.02 CAD
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.01 CAD
Buy:0.02 CAD
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

Contact details

Address:
570 Granville St Suite 900
VANCOUVER
V6C 3P1
Canada
Telephone:
+1 (604) 2488693
Website:
https://www.replicel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RP
ISIN:
CA76027P4006
Market cap:
3.58 million CAD
Shares in issue:
61.43 million
Sector:
Life Sciences Tools & Services
Exchange:
Canadian Venture Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Andrew Schutte
    President, Chief Executive Officer, Director
  • Ben Austring
    Chief Operating Officer, Corporate Secretary
  • Kevin Mcelwee
    Chief Scientific Officer
  • Rolf Hoffmann
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.